Torrent Pharmac Patent-Cliff Exposure & CMS Drug Spending Portfolio

Torrent Pharmac (US): 4 reconciled FDA prescription therapies, $163.2M 2024 CMS Part D & Medicaid spend, and $25,628 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$163.2M
2024 Medicare Part D Spend$135.9M
2024 Medicaid Spend$27.2M
California HCAI SB 17 FilingsSpecialty launch notice ($25,628 intro WAC)